BioSpace News Archive

Xcell Biosciences Inc., an instrumentation company focused on cell and gene therapy applications, announced the formation of a new scientific and business advisory board composed of some of the leading minds in the industry.

Pieris Pharmaceuticals, Inc. provided a corporate update announcing a strategy to maximize its ability to capture the potential milestones from its 4-1BB bispecific Mabcalin® protein immuno-oncology assets partnered with Pfizer, Boston Pharmaceuticals, and Servier.

Olympus Corporation of the Americas, a global medical technology company committed to making people’s lives healthier, safer and more fulfilling, is now partnering with the American Lung Association to educate lung cancer patients about the care pathway for diagnosing and staging lung nodules.

CorMedix Inc. (Nasdaq: CRMD) today announced that management will be participating in a fireside chat and investor meetings at the Needham 23rd Annual Healthcare Conference, being held virtually on April 8 – 11, 2024.

Vaccinex, Inc. announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale of 193,000 shares of its common stock in a registered direct offering together with warrants to purchase up to an aggregate of 193,000 shares of common stock in a concurrent private placement priced at-the-market under Nasdaq rules at a combined purchase price of $7.77 per share and accompanying warrant.

Jaguar Health, Inc. announced that the company will conduct an investor webcast on Monday, April 1, 2024 at 8:30 a.m. Eastern Standard Time to review fourth-quarter 2024 financials and provide corporate updates.

CARsgen Therapeutics Holdings Limited, a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2023 Annual Results.

AXIM Biotechnologies, Inc. released a fireside chat interview conducted with its CEO John Huemoeller II and Tony Noto at the 2024 Benzinga Virtual Healthcare Summit.

LogicMark, Inc. (Nasdaq: LGMK), a provider of personal emergency response systems, health communications devices, and technology for the growing care economy, today announced that it has rescheduled the release of fourth quarter and full year 2023 financial results, originally scheduled for March 27, 2024.

BlueWind Medical, Ltd., a pioneer in the development and commercialization of a patient-centric implantable Tibial NeuroModulation (iTNM) solution for urge urinary incontinence (UUI), is excited to announce that Revi is now available in Utah with urologist Dr. Sara Lenherr at the University of Utah.